Explore our diverse range of medications and therapies.
- Breast Cancer
- Bladder Cancer
- Endometrial Cancer
- Gastrointestinal Cancer
- Hematologic
- Lung Cancer
- Ovarian Cancer
- Prostrate Cancer
- Pancreatic
Breast Cancer
Explore our diverse range of medications and therapies.
ENHERTU® Safety Information
HER2-Positive Breast Cancer
ENHERTU™ (trastuzumab deruxtecan for injection) as monotherapy is indicated for:
- the treatment of adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer who have received at least one prior antiHER2-based regimen either
- in the metastatic setting, or
- in the neoadjuvant or adjuvant setting and developed disease recurrence during or within 6 months of completing neoadjuvant or adjuvant therapy.
- the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received prior treatment with trastuzumab emtansine (T-DM1).
HER2-Low Breast Cancer
ENHERTU™ as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received at least one prior line of chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.
Patients with hormone receptor positive (HR+) breast cancer should have received at least one and be no longer considered eligible for endocrine therapy.
For more information: Please consult the ENHERTU™ Product Monograph for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling us at 1-800-668-6000.
LYNPARZA® Safety Information
LYNPARZA® (olaparib) is indicated for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Patients must have confirmation of a germline BRCA mutation before LYNPARZA® treatment is initiated.
LYNPARZA® is indicated as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2- negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have progressed on or be considered inappropriate for endocrine therapy. Germline BRCA mutation must be confirmed before LYNPARZA® treatment is initiated.
For more information: Please consult the LYNPARZA® Product Monograph for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling us at 1-800-668-6000.
TRUQAP™ Safety Information
TRUQAP™ (capivasertib tablets), in combination with fulvestrant, is indicated for the treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.
For more information: Please consult the TRUQAP™ Product Monograph for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling us at 1-800-668-6000.
Bladder Cancer
IMFINZI® Safety Information
Urothelial Carcinoma
IMFINZI® (durvalumab for injection) is indicated for:
- the treatment of patients with locally advanced or metastatic urothelial carcinoma who:
- have disease progression during or following platinum-containing chemotherapy
- have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy
has been issued market authorization with conditions, pending the results of trials to verify its clinical benefit. Patients should be advised of the nature of the authorization. For further information for IMFINZI® please refer to Health Canada’s Notice of Compliance with conditions - drug products web site: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/notice-compliance/conditions.html
For more information: Please consult the IMFINZI® Product Monograph for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling us at 1-800-668-6000.
Endometrial Cancer
Explore our diverse range of medications and therapies.
IMFINZI® Safety Information
Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Cancer
IMFINZI® in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adult patients with primary advanced or recurrent mismatch repair deficient (dMMR) endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with Imfinzi as monotherapy.
For more information: Please consult the IMFINZI Product Monograph for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling us at 1-800-668-6000.
Gastrointestinal Cancer
Explore our diverse range of medications and therapies.
ENHERTU® Safety Information
HER2-Positive Gastric and Gastroesophageal Junction Cancer ENHERTU® as monotherapy is indicated for:
- the treatment of adult patients with unresectable, locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.
has been issued marketing authorization with conditions, pending the results of trials to verify its clinical benefit. Patients should be advised of the nature of the authorization. For further information for ENHERTU®, please refer to Health Canada’s Notice of Compliance with conditions - drug products web site: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/notice-compliance/conditions.html
For more information: Please consult the ENHERTU® Product Monograph for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling us at 1-800-668-6000.
IMFINZI® Safety Information
Locally Advanced or Metastatic Biliary Tract Cancer
IMFINZI® in combination with gemcitabine-based chemotherapy is indicated for the treatment of patients with locally advanced or metastatic biliary tract cancer (BTC).
Unresectable Hepatocellular Carcinoma
IMFINZI® in combination with tremelimumab is indicated for the first-line treatment of adult patients with unresectable hepatocellular carcinoma (uHCC) who require systemic therapy.
- When using Imfinzi in combination with tremelimumab, consult the Product Monograph for tremelimumab for further information on this drug. Imfinzi, as monotherapy, is indicated for the first-line treatment of adult patients with uHCC who require systemic therapy.
For more information: Please consult the IMFINZI® Product Monograph for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling us at 1-800-668-6000.
Hematologic Cancer
Explore our diverse range of medications and therapies.
CALQUENCE® Safety Information
CALQUENCE® (acalabrutinib) is indicated:
- in combination with obinutuzumab or as monotherapy for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL)
- as monotherapy for the treatment of patients with CLL who have received at least one prior therapy
- for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy
For more information: Please consult the CALQUENCE® Product Monograph for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling us at 1-800-668-6000.
Lung Cancer
Explore our diverse range of medications and therapies.
IMFINZI® Safety Information
Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer
IMFINZI® is indicated for the treatment of patients with locally advanced, unresectable, Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following platinum-based chemoradiation therapy.
Extensive-Stage Small Cell Lung Cancer
IMFINZI® in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
For more information: Please consult the IMFINZI® Product Monograph for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling us at 1-800-668-6000.
TAGRISSOTM Safety Information
EGFR Mutation-Positive NSCLC Adjuvant
TAGRISSO™ (osimertinib) is indicated as adjuvant therapy after tumour resection in patients with stage IB-IIIA1 non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations (see 14 CLINICAL TRIALS).
- A validated test is required to identify EGFR mutation-positive status prior to treatment.
Metastatic (monotherapy)
TAGRISSO™ is indicated for the first-line treatment of patients with locally advanced (not amenable to curative therapies), or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations (either alone or in combination with other EGFR mutations).
- A validated test is required to identify EGFR mutation-positive status prior to treatment.
Metastatic (in combination with chemotherapy)
TAGRISSO™ is indicated in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with locally advanced (not amenable to curative therapies) or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.
- A validated test is required to identify EGFR mutation-positive status prior to treatment.
EGFR T790M Mutation-Positive NSCLC
TAGRISSO™ is indicated for the treatment of patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.
- A validated test is required to identify EGFR T790M mutation-positive status prior to treatment.
- Marketing authorization was based on results from a randomized Phase III trial (AURA3) demonstrating that TAGRISSO™ is superior to chemotherapy in prolonging progression-free survival (PFS) as assessed by investigator using RECIST v1.1.
For more information: Please consult the TAGRISSO™ Product Monograph for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling us at 1-800-668-6000.
Ovarian Cancer
Explore our diverse range of medications and therapies.
LYNPARZA® Safety Information
Ovarian Cancer
LYNPARZA® is indicated as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy. Patients must have confirmation of BRCA mutation (identified by either germline or tumour testing) before LYNPARZA® treatment is initiated (see 14 CLINICAL TRIALS, SOLO1).
LYNPARZA® is indicated as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed (PSR) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy (see 14 CLINICAL TRIALS, SOLO2, Study 19, OPINION). Platinum-sensitive relapse is defined as disease progression occurring at least 6 months following completion of platinum chemotherapy.
For more information: Please consult the LYNPARZA® Product Monograph for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling us at 1-800-668-6000.
Prostrate Cancer
Explore our diverse range of medications and therapies.
LYNPARZA® Safety Information
Prostate Cancer
LYNPARZA® is indicated as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutated metastatic castration resistant Prostate Cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent. BRCA or ATM mutations must be confirmed before LYNPARZA® treatment is initiated.
LYNPARZA® is indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration resistant prostate cancer (mCRPC) in whom LYNPARZA® (olaparib tablets) Page 5 of 97 chemotherapy is not clinically indicated. BRCA mutation must be confirmed before LYNPARZA treatment is initiated.
For more information: Please consult the LYNPARZA® Product Monograph for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling us at 1-800-668-6000.
Pancreatic
Explore our diverse range of medications and therapies.
LYNPARZA® Safety Information
Adenocarcinoma of the Pancreas
LYNPARZA® is indicated as monotherapy for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic adenocarcinoma of the pancreas whose disease has not progressed on a minimum of 16 weeks of first-line platinum-based chemotherapy. Germline BRCA mutation must be confirmed before LYNPARZA® treatment is initiated.
For more information: Please consult the LYNPARZA® Product Monograph for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling us at 1-800-668-6000.
© 2024 AstraZeneca Canada Inc. All rights reserved.
AstraZeneca and the AstraZeneca logo are registered trademarks of AstraZeneca AB, used under license by AstraZeneca Canada Inc.
